StreetInsider.com News Articles

Form 8-K Liminatus Pharma, Inc. For: Sep 24

Tue, 29 Sep 2026 09:15:00 -0400

si-local-file:///var/storage/secattach/20260929/27118844.html

Liminatus Pharma regains Nasdaq compliance after reverse split

Tue, 29 Sep 2026 09:00:11 -0400

Liminatus Pharma, Inc. (Nasdaq: LIMN) announced it has regained compliance with Nasdaq's minimum bid price rule, according to a company press release.

The biotechnology company had received a notice from Nasdaq on January 15, 2026, indicating its common stock closing bid price had fallen below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1) for the Nasdaq Global Market.

Following an appeal and hearing, the Nasdaq Hearings Panel transferred the company to the Nasdaq Capital Market effective August 4, 2026, and granted an extension to demonstrate compliance with Listing Rule 5550(a)(2) by September 3, 2026.

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Tue, 29 Sep 2026 09:00:00 -0400

FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.

As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below $1.00 for 30 consecutive business days, and, consequently, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the applicable minimum bid price requirement for The Nasdaq Global Market).

Following an appeal and

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

Tue, 29 Sep 2026 09:00:00 -0400

Following an appeal and

Liminatus Pharma hires Korean CRO to advance CAR-T clinical trial

Mon, 24 Aug 2026 08:00:22 -0400

Liminatus Pharma, Inc. (Nasdaq: LIMN) has engaged Synex Consulting Ltd., a Korea-based contract research organization, to support the Phase 1/2a clinical development of IBC101, its CD19xCD22 bivalent CAR-T cell therapy candidate, according to a press release.

IBC101 has received authorization from South Korea's Ministry of Food and Drug Safety for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma. Seoul St. Mary's Hospital has been identified as the lead clinical site.

Under the agreement, Synex will provide clinical research services through a milestone-based payment structure tied to patient enrollment, database lock, and completion of the clinical

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Mon, 24 Aug 2026 08:00:00 -0400

Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies

FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. (“Synex”), a Korea-based full-service contract research organization (“CRO”), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Mon, 24 Aug 2026 08:00:00 -0400

Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. (“Synex”), a Korea-based full-service contract research organization (“CRO”), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Mon, 24 Aug 2026 08:00:00 -0400

Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. (“Synex”), a Korea-based full-service contract research organization (“CRO”), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

Mon, 24 Aug 2026 08:00:00 -0400

Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. (“Synex”), a Korea-based full-service contract research organization (“CRO”), to support the clinical development of IBC101, the Company’s CD19xCD22 bivalent CAR-T cell therapy candidate.

The engagement represents an important step in advancing IBC101 toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and

Form 8-K Liminatus Pharma, Inc. For: Aug 18

Tue, 18 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260818/26944224.html

Form 8-K Liminatus Pharma, Inc. For: Aug 18

Tue, 18 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260818/26944224.html

Liminatus Pharma announces 1-for-50 reverse stock split

Tue, 18 Aug 2026 16:01:11 -0400

Liminatus Pharma, Inc. (Nasdaq: LIMN) announced that its board of directors has approved a 1-for-50 reverse stock split of its common stock, effective at the close of trading on August 20, 2026.

The company's common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol "LIMN" at the market open on August 21, 2026. The new CUSIP number for the common stock will be 53271X 207.

Stockholders approved the reverse stock split at the company's 2026 Annual Meeting of Stockholders held on August 3, 2026.

Under the terms of the split, every 50

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Tue, 18 Aug 2026 16:01:00 -0400

FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the Company’s 2026 Annual Meeting of Stockholders held on August 3, 2026. The Reverse Stock Split will take effect at the close of trading on August 20, 2026, and the Company’s Common Stock is expected to begin trading on

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

Tue, 18 Aug 2026 16:01:00 -0400

FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value $0.0001 per share (“Common Stock”), at a ratio of 1-for-50 (the “Reverse Stock Split”), which was approved by stockholders at the Company’s 2026 Annual Meeting of Stockholders held on August 3, 2026. The Reverse Stock Split will take effect at the close of trading on August 20, 2026, and the Company’s Common Stock is expected to begin trading on

Form 10-Q Liminatus Pharma, Inc. For: Jun 30

Fri, 14 Aug 2026 16:51:00 -0400
si-local-file:///var/storage/secattach/20260814/26932233.html

Form 10-Q Liminatus Pharma, Inc. For: Jun 30

Fri, 14 Aug 2026 16:51:00 -0400
si-local-file:///var/storage/secattach/20260814/26932233.html

Liminatus Pharma moves to Nasdaq Capital Market amid bid price issue

Thu, 13 Aug 2026 07:15:07 -0400

Liminatus Pharma, Inc. (NASDAQ: LIMN) announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, according to a company press release.

The Nasdaq Hearings Panel has granted the biopharmaceutical company an extension to demonstrate compliance with Nasdaq's minimum bid price requirement, giving the company until September 3, 2026 to meet the standard.

The company's shares will continue trading under the ticker symbol "LIMN" during the extension period, subject to compliance with the panel's decision and other applicable Nasdaq continued listing requirements.

"We are pleased to have completed the transfer to the Nasdaq

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Thu, 13 Aug 2026 07:15:00 -0400

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement.

The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, “LIMN.” The

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

Thu, 13 Aug 2026 07:15:00 -0400

FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, today announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026, and that the Nasdaq Hearings Panel (the “Panel”) has granted the Company additional time to demonstrate compliance with Nasdaq’s minimum bid price requirement.

The transfer to the Nasdaq Capital Market allows the Company’s common stock to continue trading on Nasdaq under its existing ticker symbol, “LIMN.” The

Form 8-K Liminatus Pharma, Inc. For: Aug 03

Tue, 04 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260804/26867061.html

Form 8-K Liminatus Pharma, Inc. For: Aug 03

Tue, 04 Aug 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260804/26867061.html

Form 8-K Liminatus Pharma, Inc. For: Jul 29

Thu, 30 Jul 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260730/26837893.html

Form 8-K Liminatus Pharma, Inc. For: Jul 29

Thu, 30 Jul 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20260730/26837893.html

Form 8-K Liminatus Pharma, Inc. For: Jul 20

Fri, 24 Jul 2026 16:51:00 -0400
si-local-file:///var/storage/secattach/20260724/26814127.html

Form 8-K Liminatus Pharma, Inc. For: Jul 20

Fri, 24 Jul 2026 16:51:00 -0400
si-local-file:///var/storage/secattach/20260724/26814127.html